GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Cyclically Adjusted Revenue per Share

Mallinckrodt (Mallinckrodt) Cyclically Adjusted Revenue per Share : $50.75 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mallinckrodt's adjusted revenue per share for the three months ended in Sep. 2023 was $37.090. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $50.75 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Mallinckrodt's average Cyclically Adjusted Revenue Growth Rate was 38.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-28), Mallinckrodt's current stock price is $0.12. Mallinckrodt's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $50.75. Mallinckrodt's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Mallinckrodt was 0.78. The lowest was 0.01. And the median was 0.20.


Mallinckrodt Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Mallinckrodt's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Cyclically Adjusted Revenue per Share Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 31.70 40.39

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.72 40.39 43.56 46.72 50.75

Competitive Comparison of Mallinckrodt's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Cyclically Adjusted PS Ratio falls into.



Mallinckrodt Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mallinckrodt's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=37.09/120.7077*120.7077
=37.090

Current CPI (Sep. 2023) = 120.7077.

Mallinckrodt Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 9.250 99.875 11.179
201403 9.438 100.573 11.327
201406 11.164 100.773 13.373
201409 -1.186 100.474 -1.425
201412 6.605 99.576 8.007
201503 6.988 99.975 8.437
201506 7.447 100.573 8.938
201509 3.911 100.274 4.708
201512 6.975 99.676 8.447
201603 8.196 99.676 9.925
201606 8.872 101.072 10.596
201609 5.336 100.274 6.423
201612 7.851 99.676 9.508
201703 7.827 100.374 9.413
201706 8.354 100.673 10.017
201709 6.192 100.474 7.439
201712 15.828 100.075 19.091
201803 8.772 100.573 10.528
201806 9.886 101.072 11.807
201809 9.411 101.371 11.206
201812 10.011 100.773 11.991
201903 9.345 101.670 11.095
201906 9.825 102.168 11.608
201909 8.854 102.268 10.450
201912 9.559 102.068 11.305
202003 7.907 102.367 9.324
202006 1.970 101.769 2.337
202009 8.254 101.072 9.858
202012 8.052 101.072 9.616
202103 6.596 102.367 7.778
202106 6.451 103.364 7.533
202109 5.988 104.859 6.893
202112 7.051 106.653 7.980
202203 5.796 109.245 6.404
202206 4.525 112.734 4.845
202209 41.697 113.431 44.372
202212 37.068 115.425 38.765
202303 32.167 117.618 33.012
202306 35.985 119.611 36.315
202309 37.090 120.708 37.090

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Mallinckrodt  (OTCPK:MCKPF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mallinckrodt's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.12/50.75
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Mallinckrodt was 0.78. The lowest was 0.01. And the median was 0.20.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mallinckrodt Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Industry
Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus